The subject invention provides fungal extracts, fungal metabolites, pharmaceutical compositions comprising the fungal extracts, and/or fungal metabolites, methods of preparation, and therapeutic uses thereof. The subject invention also provides a bioactive agent and a composition comprising the bioactive agent, and therapeutic uses thereof. The subject invention further provides methods for treating, inhibiting and/or preventing malaria infection and transmission by using the fungal extracts, fungal metabolites, bioactive agents, and pharmaceutical compositions comprising the fungal extracts, fungal metabolites, and/or bioactive agent.

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Novel biocompatible Fenton-catalytic nano-particulate composites preferably based on nanoparticle (NP)-based catalysts, one or more reducing agents, and one or more peroxide compounds are formulated to take advantage of their ability to stimulate bactericidal as well as anti-tumor immune response by means of eliciting the generation of reactive oxygen species (ROS) in immune cells, in particular, in macrophages. The therapeutic composition can serve as a treatment for wound infections by, but not limited to, Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Klebsiella pneumoniae, and Acinetobacter baumannii, as a wound/lesion dressing that provide an anti-bacterial immune environment for the accelerated wound healing. In a similar principle, the therapeutic composition can serve as a treatment for solid tumors by providing an anti-tumor immune environment that inhibits tumor growth.

Novel biocompatible Fenton-catalytic nano-particulate composites preferably based on nanoparticle (NP)-based catalysts, one or more reducing agents, and one or more peroxide compounds are formulated to take advantage of their ability to stimulate bactericidal as well as anti-tumor immune response by means of eliciting the generation of reactive oxygen species (ROS) in immune cells, in particular, in macrophages. The therapeutic composition can serve as a treatment for wound infections by, but not limited to, Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Klebsiella pneumoniae, and Acinetobacter baumannii, as a wound/lesion dressing that provide an anti-bacterial immune environment for the accelerated wound healing. In a similar principle, the therapeutic composition can serve as a treatment for solid tumors by providing an anti-tumor immune environment that inhibits tumor growth.

Provided are a novel tricyclic dilactone compound, a strain producing the same, a method of producing the tricyclic dilactone compound, and use of the tricyclic dilactone compound. The tricyclic dilactone compound has activity of inhibiting aggregation of amyloid-beta and tau proteins, activity of inhibiting apoptosis, and anti-inflammation activity, and thus may be used to prevent, treat, or improve various neurodegenerative brain diseases including Alzheimer's disease and cognitive impairment.

Pharmaceutical or nutraceutical formulations are provided for treating inflammation in a subject in need thereof, as well as methods of treating inflammation in a subject in need thereof by administering one of the formulations. In some aspects, the pharmaceutical or nutraceutical formulation includes an effective amount of (i) palmitoylethanolamide or a derivative thereof, and (ii) one, two, three or more different small-molecule polyphenols or derivatives thereof to alleviate one or more causes or symptoms of the inflammation in the subject. In some aspects, the formulations include all three, e.g. the formulations includes (i) palmitoylethanolamide or a derivative thereof, (ii) quercetin or a derivative thereof, and (iii) curcumin or a derivative thereof. In some instances, the components (i)-(iii) discussed above are present at a mass ratio of about (i) 4 mg to 6 mg of palmitoylethanolamide or a derivative thereof to (ii) about 0.5 to 2.5 mg curcumin or a derivative thereof, and (iii) about 0.5 mg to 1.5 mg quercetin or a derivative thereof.

Pharmaceutical or nutraceutical formulations are provided for treating inflammation in a subject in need thereof, as well as methods of treating inflammation in a subject in need thereof by administering one of the formulations. In some aspects, the pharmaceutical or nutraceutical formulation includes an effective amount of (i) palmitoylethanolamide or a derivative thereof, and (ii) one, two, three or more different small-molecule polyphenols or derivatives thereof to alleviate one or more causes or symptoms of the inflammation in the subject. In some aspects, the formulations include all three, e.g. the formulations includes (i) palmitoylethanolamide or a derivative thereof, (ii) quercetin or a derivative thereof, and (iii) curcumin or a derivative thereof. In some instances, the components (i)-(iii) discussed above are present at a mass ratio of about (i) 4 mg to 6 mg of palmitoylethanolamide or a derivative thereof to (ii) about 0.5 to 2.5 mg curcumin or a derivative thereof, and (iii) about 0.5 mg to 1.5 mg quercetin or a derivative thereof.

The present invention relates to an inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition, wherein said archaeon is in the gut of a subject and is characterized by the production of 2-hydroxypyridine. In addition, the present invention relates to a pharmaceutical composition comprising such an inhibitor and a kit comprising such an inhibitor. Further, the present invention relates to a method of screening for an inhibitor for use according to the present invention and a method for determining whether or not a subject is susceptible to a treatment with an inhibitor for use according to the present invention.